NanoViricides, Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended June 30, 2019. Although the request metadata refers to 2018 Q4, this filing is an annual report for FY2019; the filing does not provide a separate Q4 summary.
Business context
NanoViricides is a development-stage antiviral drug company. It had no approved products, customers, or revenue. Its lead program was a topical shingles treatment candidate, NV-HHV-101, alongside preclinical programs for other herpesvirus indications and additional viruses. Most development work is performed with TheraCour Pharma and outside collaborators.
Financial performance and liquidity
| Metric | FY2019 / June 30, 2019 | FY2018 / June 30, 2018 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $5.922 million | $5.914 million |
| General and administrative expense | $2.738 million | $3.411 million |
| Total operating expenses | $8.660 million | $9.325 million |
| Net loss | $8.424 million; $0.12 per share | $8.563 million; $0.13 per share |
| Cash used in operating activities | $6.803 million | $7.776 million |
| Cash and cash equivalents | $2.555 million | $7.082 million |
| Working capital | $(22,732) | $6.440 million |
| Total assets | $13.449 million | $18.546 million |
| Current liabilities | $2.848 million | $881,948 |
| Stockholders’ equity | $10.600 million | $17.664 million |
No revenue means operating margins are not meaningful. The company reported no long-term debt at June 30, 2019. Its accumulated deficit was $92.117 million. The auditor issued an unqualified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern.
Changes, financing, and unusual items
- Net loss narrowed by about $139,000, principally alongside lower G&A and the absence of prior-year debt-related expenses; operating expenses fell about $665,000 overall.
- Cash declined by $4.527 million during FY2019. The company raised $2.5 million gross, or $2.35 million net after offering costs, in a February 2019 registered offering of 6.944 million shares. Investors also received warrants for up to 6.944 million shares at $0.61 each, exercisable for five years; warrant accounting produced a $1.646 million derivative liability at year-end.
- Accounts payable to related party TheraCour increased to $823,783, including $300,000 deferred until an IND filing. FY2019 development and other costs charged by TheraCour were $3.120 million. TheraCour is controlled by company President Anil Diwan, creating related-party and governance considerations.
- The company had approximately 76.9 million common shares outstanding at June 30, 2019, up from 69.2 million a year earlier.
Outlook, risks, and contingencies
- Management prioritized NV-HHV-101 for shingles. The FDA’s May 2019 pre-IND response generally agreed that the proposed nonclinical plan and initial clinical-study design appeared adequate; this was not an IND clearance or marketing approval. The GLP toxicology study was underway at year-end; the company reported subsequent completion of its in-life portion in August 2019.
- Management planned to complete IND-enabling work and seek to begin Phase I, with Phase II possible if resources and timing allowed. The filing gives no assured clinical start date and notes dependence on external collaborators.
- Management estimated roughly $7 million in cash expenditures for the next 12 months and about $21 million of additional funding over the following two years for development and clinical work. It said additional financing was necessary and described runway estimates as conditional; elsewhere it warned operations could not proceed beyond approximately September 30, 2019 without additional financing. There was no definitive financing agreement disclosed.
- The company reported no commercial revenue prospects in the near term, substantial continuing R&D costs, reduced staffing, and risks from clinical failure, regulation, competition, financing needs, and reliance on TheraCour. A definitive VZV license from TheraCour was still being negotiated, despite an executed memorandum of understanding.
- Disclosure controls and internal control over financial reporting were deemed ineffective due to material weaknesses involving review of the Form 10-K, third-party valuation reports, and income taxes. Management described remediation measures.
- No material legal proceedings were reported. The filing reports no long-term debt and no off-balance-sheet arrangements for FY2019.
Key facts investors should verify
- Current cash runway, subsequent financing, and whether funding is sufficient to meet operating and clinical-development plans.
- Status and terms of the definitive TheraCour license for VZV, including related-party approvals and deferred balances.
- Completion and results of the full IND-enabling toxicology and CMC package, IND submission, and any FDA response.
- Whether clinical trials began, their design, costs, funding source, and any human safety or efficacy data.
- Potential dilution from outstanding warrants, future equity financing, and the terms of any new capital raises.
- Progress in remediating the disclosed internal-control weaknesses and any subsequent changes in management or controls.